$EXPD

Expeditors International of Washington (EXPD) reported Q2 2026 results with revenue of $3,502.34 million and net income of $266.23 million, and continued share repurchases. The company said it has bought back 121,978,285 shares for about $9.37 billion since 2001, including another $348.45 million in buybacks. Simply Wall St discusses EPS and fair value estimates of about $168 to $178.

Expeditors International of Washington (EXPD) reported Q2 2026 revenue of $3,502.34 million and net income of $266.23 million, with both up year over year, according to the company. The article says EXPD completed a buyback program first announced in 2001 and still had unused capital under a newer 2026 authorization.

Expedition raised $115m in a Series B to advance its COPD drug EXPD-101 through an ongoing Phase II trial (NCT07684820), and to expand its pipeline and discovery platform, according to CEO Yi Larson. EXPD-101 targets neutrophilic inflammation via DPP1 inhibition. The company cited prior Phase I results showing tolerability and once-daily oral dosing support.

Analyst actions highlighted: Argus upgraded Bristol Myers (BMY) to Buy, $75 target, citing margin improvement and raised 2026 guidance. Freedom Broker upgraded McDonald's (MCD) to Buy, $305 target, on softer revenue and comps. Morgan Stanley upgraded Humana (HUM) to Equal Weight, $370 target. Jefferies downgraded Best Buy (BBY) to Hold, $85 target. Others included upgrades/downgrades for several stocks with updated price targets.

The NYSE pre-market update says the Dow rose above 54,000 for the first time and the S&P 500 closed above 7,700. It notes Expedition Therapeutics secured a $115 million Series B and that first patients were dosed in its Phase 2 trial for EXPD-101 in COPD. It also references Zeta Global’s Q2 beat-and-raise results.

EXPEDITORS INTERNATIONAL OF WASHINGTON INC (EXPD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 expd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 EARNINGS RELEASE By: Expeditors International of Washington, Inc. 3545 Factoria Blvd. SE Sterling Plaza 2, 3rd Floor Bellevue, Washington 98006 CONTACTS : Daniel R. Wall David A. Hackett Geoffrey Buscher President and Chief E

Expeditors International reported Q2 results with airfreight volume up 14% year over year (13% April, 14% May, 15% June). Ocean freight was mixed, flat overall. Revenue rose 32% to $3.5B, operating income up 41% to $349.6M, and net income to $2.03 per share. CEO Daniel Wall cited strong air demand and tariff-driven customs activity.

Expeditors International of Washington (EXPD) reported Q2 earnings of $266.2 million, or $2.03 per share, up from $183.6 million, or $1.34 per share, a year earlier. Revenue increased 32% to $3.502 billion from $2.651 billion. The company said results reflected double-digit growth across most products. EXPD last traded at $171.89 on the NYSE.

Expeditors (NYSE:EXPD) reported Q2 CY2026 revenue of $3.50 billion, up 32.1% year on year and 18.6% above Wall Street estimates, and GAAP EPS of $2.03, 19.9% above consensus. The board declared a semi-annual dividend of $0.81 per share payable June 15, 2026. Analysts expect revenue growth of 1.1% over the next 12 months.

Expeditors (NYSE: EXPD) is set to report Q2 results Tuesday before the bell. The article notes last quarter’s revenue was $2.78B, up 4.4% YoY, and it beat analysts on EPS. For this quarter, analysts expect revenue growth of 11.4% YoY. It cites an average price target of $157.14 versus a $166.75 share price.